Maks_Lab
- China National Pharmaceutical Group, also known as Sinopharm (OTCPK:SHTDY) (OTCPK:SHTDF), is among entities exploring a potential acquisition of China-based DNA synthesis product provider BBI Life Sciences which could be valued over $1B, Bloomberg News reported citing people with knowledge of the matter.
- Sinopharm has been in discussions with the Wang family, BBI's founders, for a potential deal. BBI is also in discussions with other potential acquirers, said the report.
- Shanghai-based BBI provides DNA synthesis, antibody and life sciences research consumable products, and genetic engineering services. The company went public on the Hong Kong exchange in 2014 but was taken private after about six years by the Wang family in an HK$845M transaction.